ArticleEpidemiologia (Basel, Switzerland)2025
COVID-19 Seroprevalence in Romania: Insights from a Nationwide Antibody Study.
Article in Epidemiologia (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrequency indicators are used by epidemiologists to facilitate public health professionals in estimating the impact of diseases. As of April 2022, Romania had reported 2.8 million confirmed COVID-19 cases to the World Health Organization, equating to a prevalence rate of 13.94%. A more accurate method for assessing the cumulative number of cases is the use of seroprevalence studies. This study retrospectively evaluates infection trends in Romania to enhance understanding of the virus's spread and may support future comparative analyses of public health responses and community-level immunity.
methodsWe analyzed 51,533 qualitative test results for high-affinity IgG antibodies targeting the SARS-CoV-2 nucleocapsid protein.
resultsThe largest proportion of tested individuals (59.4%) was aged 18-49 years. Among all serological tests, 18,980 were positive, corresponding to an adjusted seroprevalence rate of 40%.
conclusionsDuring the second year of the pandemic, seropositivity rates were highest among young adults, particularly in the western regions, and lowest among children and adolescents. These findings point out variations in exposure across age groups and geographic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.